+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Therapeutic use of ganciclovir for invasive cytomegalovirus infection in cadaveric renal allograft recipients



Therapeutic use of ganciclovir for invasive cytomegalovirus infection in cadaveric renal allograft recipients



Journal of Urology 148(5): 1388-1392



Between November 1987 and September 1989, 419 cadaveric renal transplants were performed at our university. Of the patients 36 (8.6%) had invasive cytomegalovirus infection documented by gastric or duodenal mucosal biopsy in 23 (64%), bronchoalveolar lavage in 12 (33%), allograft biopsy or nephrectomy specimen in 5 (14%) and/or liver biopsy in 1 (3%). Cytomegalovirus severity was defined as mild in 27 patients, moderate in 6 and severe in 3. Ganciclovir [9-(1,3-dihydroxy-2-propoxymethyl)-guanine] was begun once the diagnosis was confirmed by histology or culture at a median of 56 days from transplantation (range 28 to 133 days). Duration of ganciclovir therapy was a minimum of 7 days or until fever was absent for 5 consecutive days (mean 12.2 +/- 3.5 days, range 4 to 21). Ganciclovir was well tolerated and side effects were limited to de novo neutropenia (7 patients), thrombocytopenia (2) and rash (1). Initial clinical improvement was observed in all patients. Two patients had recurrent cytomegalovirus infections that responded to a second course of ganciclovir. The 1-year actuarial patient survival was 100%. At a mean followup of 12.7 +/- 6.2 months 19 patients retained allograft function with a mean serum creatinine of 2.5 mg./dl. (range 1.2 to 4.6). Ganciclovir appears to be a safe and effective drug for the treatment of tissue invasive cytomegalovirus infection in cadaver renal transplant recipients. Prompt institution of this drug at diagnosis of invasive cytomegalovirus may lower the mortality rate formerly associated with this disease.

(PDF emailed within 0-6 h: $19.90)

Accession: 009640300

Download citation: RISBibTeXText

PMID: 1331542

DOI: 10.1016/s0022-5347(17)36918-5


Related references

Ganciclovir for invasive cytomegalovirus infection in renal allograft recipients. Transplantation Proceedings 23(1 Pt 2): 1346-1347, 1991

Impact of ganciclovir prophylaxis on CMV infection in cadaveric renal allograft recipients. Journal of the American Society of Nephrology 5(3): 1032, 1994

Ganciclovir for cytomegalovirus cmv infection in renal allograft recipients. Journal of Urology 145(4 SUPPL): 304A, 1991

Impact of Ganciclovir Prophylaxis on Cytomegalovirus Infection in Recipients of Cadaveric Renal Al log rafts. Nephron 76(1): 49-55, 1997

Impact of ganciclovir prophylaxis on cytomegalovirus infection in recipients of cadaveric renal allografts. Nephron 76(1): 49-55, 1997

Treatment of active cytomegalovirus disease with oral ganciclovir in renal allograft recipients: monitoring efficacy with quantitative cytomegalovirus polymerase chain reaction. American Journal of Transplantation 2(7): 671-673, 2002

Effectiveness of deferred therapy with ganciclovir in renal allograft recipients with cytomegalovirus disease. Transplantation Proceedings 30(5): 2083-2085, 1998

A randomized comparison of ganciclovir and acyclovir for prevention of cytomegalovirus infection in lung allograft recipients. Pharmacotherapy 12(6): 508, 1992

Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients. Transplantation 70(8): 1174-1180, 2000

Efficacy and safety of valaciclovir for suppression of cytomegalovirus disease in recipients of a cadaveric renal allograft. Kidney & Blood Pressure Research 21(2-4): 162, 1998

Ganciclovir for cytomegalovirus infection in renal transplant recipients. Lancet 1(8631): 216-217, 1989

Valaciclovir reduces the incidence of other opportunistic infections in cytomegalovirus-seronegative recipients of a seropositive cadaveric renal allograft. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 340, 1998

The incidence of cytomegalovirus infection and the effects of immunosuppressants on cytomegalovirus infection in renal allograft recipients. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 728A, 2000

Ganciclovir therapy of symptomatic cytomegalovirus infection in renal transplant recipients. Nephrology, Dialysis, Transplantation 4(10): 906-910, 1989

Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients. Nephrology, Dialysis, Transplantation 8(9): 858-862, 1993